Member Info for Computer909

@tsales, because when you consider the negative and positive sides of any investment you are better informed and prepared for whatever happens in the movement of the Sp

@Bushmaster, i’m not relying on their market prediction , but they do have a secured market share and a lot more market prediction resources than i do, being as i said the third largest pharma in the World

For all i know the could have decided that their market share was unpredictable because ODX were going to take over their global sales!

It was just supporting the uncertainty point

@Tsales, and what agenda, oh let me guess i want your shares, i have enough thanks, if you feel you cant question everything your investment is doing you shouldn’t be invested, please take the opportunity to make the “positive” contribution to the discussion as others are doing

@Bushmaster, i never said testing wasnt going be needed into H2, i only said Roche were unable to predict the market that far ahead, so saying “worst case” wasnt a something we could be confident with, so until we get more details on the revenue being secured we are all guessing, i hope the details are set out clearly rather than Colin’s usual cryptic way.

@Dm83, the issue is that Roche were unable to attribute (or at least unwilling) to project any revenue from covid beyond H1-2020, with us now not selling anything until april, that only gives us 2 to 3 months where the third biggest pharma in the world is confident the covid market is certain, also remember the £912m tender has supply dates from 5th Feb to 31st march beyond that the uncertainty persists

@Dm83, your calculations assume a full years production to get to the 100m tests pa, we have previously discussed Roche’s reluctance to project any covid sales beyond H1 of this year, as the market is simply unknown, so not sure we can say “worst case” as its simply too fluid a situation

@tuam6, if you are referring to ABC-19 antibody tests, ODX are contract manufacturers for that test so DHSC cant deal direct from us, that has to be purchased through ABDX

The loan equipment is for the UK antigen consortium production

@busmaster, i think the point was does the loan equipment come with strings attached, i.e lower margins, when we expected to be able to command a premium from our own 2m visitect branded tests

@tuan6, so you bought based on DHSC contract news?, interested at what made you jump in at this point?

@Takingiteasy, what i meant was the revenue stream decreased by 45% even with the investment of £1.1m, perhaps that additional investment wasn't the best thought through

“other (ELISA and labs-based) sales to have fallen 45% to c.£0.5m" for example” , after investing £1.1M on this stream, and some people ask why we question the activity over the last 9 months,

@Disciple13, i have supported ODx, and continue to do so in a large way since may , feel free to use the “la la la” button if you cant offer anything to the discussion, dont make out everything is going smimmingly, it isnt, or actually what i mean is that it hasnt been all year

I just wish we would stop banging on about capacity and instead report on actual production or sales, lets remember Elisa capacity of 46k per day since September, LFT capacity going unused all year, based on the posted returns what have they been doing all year?

@takingiteasy, do you think we need news in the form similar to Novacyt contract announcement (ie the contract is worth x million pounds over the next y weeks, in order to remove the speculation?

@themorg, do you know we will be making and selling 2m tests, the only statement we have had is around capacity, they have also stated that capacity will be enough to cover the other test production, so will we be maxed?

@Scaff55, I hope ( and it looks promising in my view) that the mologic test will be one of the tests selected for the dhsc brand, this would mean we could run one production line and then just package differently depending on demand, and we are already started on the tech transfer / CE work,( however long that takes)

@Mathersfinger, it does say Share discussion on the top of this page, let’s discuss, show some details that support the statement ,”ODX are going great guns”, their posted update doesnt support that, the dhsc contract should be a turning point but no information yet, so the should is still operative word

@asher7, please do, if you cant offer a more sensible argument than “they want your shares” you aren’t adding anything to the discussion, i have plenty already thanks

@snowking, you clearly prove the point, nowhere has the company ever mentioned the plan to loan equipment in order to ramp up capacity, they have always stated cash from the placing would be used, so lets have some info on the change rather than dropping the bomshell without any explanation, after all it was investors that took up the placing that provided the cash which was supposed to be used for it.

Lack of clear information that we can rely on from the company always makes things open to interpretation and produces uncertainty in the PI, and remember the thread is about MM manipulation, allow the share to be thrashed over and over again.

@kevman72, Interesting clip, but it all relies on the fact that the PI's have no confidence in the share, the MM's cant build a liquidity pool if no one wants to sell, and no one wants to sell if they are confident with their position.

The problem with ODX is too much promise, so little delivery, its now gone from Jam tomorrow to Jam next year, We have been spending money on what now appears to be fools gold.

ELISA Testing - £1.1M allocated from the placing (zero sales)
CV-19 production upscale - £3.0M allocated from the placing (barely any sales) and now we find out we have to borrow equipment to meet the 2M a week target, A poster on advfn summed it up with the statement saying, our world leading production line looks like a primary school science lab without the bunsen burners, they aren't wrong.

If you consider these investment and the £1.5M posted returns we have made £2.8M loss on our covid revenue streams to date.

The resistance point of £1 seems to be a level we can't break through, Colin's crap RNS's and i'll thought-out tweets do nothing to calm the nerves of PIs that become nervous seeing their investment rise and fall at the drop of a tweet.

Colin seems unable or unwilling to offer firm dates and figures around anything they are doing, so we must wait for news (or sell up and move on), but past delivery from ODX is questionable to say the least, there is no way a world leading diagnostics company should be posting a loss in the current crisis.

We all still holdout that the Mologic TT and CE will turn the picture around, I still think that will push us through the £1 again, but not sure if even that without some sales agreements will be enough to keep us up there, the market just doesn't trust the SP can hold that level and needs news to steady the ship.

The point being that Market Makers can only manipulate the PIs if they are uncomfortable with their positions, and that has a lot to do with the company themselves and the way the keep their investors informed.